Shenzhen Zhongjia Biomedical Technology Co., Ltd. Shenzhen Zhongjia Biomedical Technology Co., Ltd.

About Us

About Us

About Zhongjia

Shenzhen Zhongjia Biomedical Technology Co., Ltd. (hereinafter referred to as "Zhongjia Bio") is a national high-tech enterprise dedicated to biomedical technology R&D and innovation. It has made deep inroads into the cell and gene therapy (CGT) field, ranking among the top CGT companies in China. Relying on full-industry-chain technological innovation and a high-standard quality system, the company has provided core technical support to nearly 1,000 Grade-A tertiary hospitals, research institutions, and CGT R&D enterprises nationwide. Zhongjia Bio actively pursues a globalization strategy, building products and services that meet international quality standards. Thanks to its outstanding technical R&D barriers and reliable product quality, its services now cover the United States, Canada, Southeast Asia, and other countries and regions, making it one of China's representative enterprises exporting high-standard CGT to the world. The company is committed to breaking down key technical barriers in biomedicine, demonstrating strong Chinese scientific and technological strength on the international track of innovative CGT drugs and technical services.

Zhongjia Bio possesses strong industrialization strength and R&D foundations, with a 12,000-square-meter pharmaceutical building meeting GMP standards (Yinxing Base) and a 1,600-square-meter cutting-edge R&D center (Gaoke Base). Driven by independent innovation, the company has successfully mastered 19 core industry technologies and built 9 innovative R&D platforms. It has passed dual international certifications of ISO 9001:2015 (Quality Management System) and ISO 13485:2016 (Medical Device Quality Management System), and obtained 4 U.S. FDA DMF filings, ensuring compliance, safety, and international quality throughout the entire product lifecycle. As a leader in industry standardization, Zhongjia Bio led the drafting of the industry standard "Preparation Specification for Human Blood-Derived Natural Killer Cell Products." With outstanding scientific research and transformation capabilities, the company has been recognized as a National High-tech Enterprise, Synthetic Biology Enterprise, Specialized, Refined, Unique and Innovative Enterprise, and approved to establish a Guangdong Provincial Doctoral Innovation Station and a Shenzhen Postdoctoral Innovation Practice Base, continuously building a highland of high-end talent and scientific innovation. Guided by the national innovation-driven development strategy, Zhongjia Bio has taken the lead in clinical trials of multiple cutting-edge cell-based drugs targeting neurodegenerative diseases, tumors, diabetes, and other conditions, continuously promoting the standardization and large-scale development of China's CGT industry. Ranking at the forefront of China's CGT industry and radiating to North America and Southeast Asia, Zhongjia Bio reshapes the miracle of life with core technology, building a world-leading full-industry-chain service platform for cell and gene therapy.

Zhongjia Bio always adheres to the core development philosophy of "Technology Leadership, Safety First," embedding high-standard quality management throughout the closed loop of the full industry chain: from cutting-edge R&D, to large-scale production, to clinical application. Upholding the corporate mission of "Forge Core Technology; Quality Matters More Than Life," the company is committed to providing customers with safe, reliable, and efficient CGT products and services through a strict compliance system and superior technical quality.

Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd.

Milestones

2026

In 2026, Zhongjia Biotech received a special fund of RMB 26 million from the Shenzhen Municipal Development and Reform Commission to tackle MLD cell therapy technology, and simultaneously carried out multiple self-developed clinical studies as well as clinical research on CD73+NK cells for cognitive disorders.
The company's multi-center clinical study of CD73+NK cells (ZJ-S-0106) for the treatment of mild-to-moderate Alzheimer's disease was filed with the National Health Commission (MR-N-44-2026-000065). After completing academic and ethical review, ethics approvals were obtained from several Class A tertiary hospitals, including Shenzhen Second People's Hospital, Tongji Hospital of Wuhan and Union Hospital of Wuhan, and the multi-center clinical trial was fully launched.

2025

February: Zhongjia Biotech's NK cell serum-free culture medium completed U.S. FDA DMF filing (DMF numbers: 044283, 041367, 043401, 043469)

March: The group standard 'Preparation Specification for Human Blood-Derived Natural Killer Cell Products', drafted under the leadership of Zhongjia Biotech, was approved and released by the China Food and Drug Enterprise Quality and Safety Promotion Association

June: Zhongjia Biotech launched the IND application for a cell therapy drug - gene-edited HSC for the treatment of MLD

November: Zhongjia Biotech launched new HSC, iPSC, NSC and HFSC culture media

December: Shenzhen Postdoctoral Innovation Practice Base; Guangdong Provincial Doctoral Innovation Station

2024

Zhongjia Biotech built a new R&D and production base with a construction area of 12,000 square meters in the Guangming Yinxing Synthetic Biology Industrial Park adjacent to Sun Yat-sen University (Shenzhen). In cooperation with Shenzhen Second People's Hospital, Zhongjia launched the preclinical research project 'IIT Study on the Rehabilitation Effect of ZJ-S-0106 on Cognitive Dysfunction', with plans for multi-center registration and an Investigational New Drug (IND) application.

2023

Recognized as an Innovative Small and Medium-sized Enterprise

Recognized as a Technology-based Small and Medium-sized Enterprise

Recognized as a Synthetic Biology Enterprise

Recognized as a Specialized, Refined, Distinctive and Innovative (SRDI) Enterprise

In the same year, Zhongjia Hospital was built and officially opened

2022

The company was recognized as a National High-tech Enterprise.

2021

The company completed its angel round of financing, accelerating its development once again. SGS audited and issued the ISO 9001 quality system certificate and the ISO 13485 quality system certificate. The company also obtained Class I medical device production filing and Class II medical device business filing.

2020

Zhongjia, together with Harvard Medical School and Brigham and Women's Hospital in the United States, jointly launched the 'Clinical Research on Innovative Cell Drugs for AKI and CKD' project and obtained an Investigational New Drug (IND) clinical trial approval in the United States.

2019

Shenzhen Jiake Biotechnology Co., Ltd. separated production from R&D and, on this basis, established Shenzhen Zhongjia Biomedical Science and Technology Co., Ltd. In the same year, a new R&D and production base was built in Guangming District, Shenzhen.

2018

Jiake and Shenzhen Second People's Hospital jointly carried out the clinical trial 'BsAb-NK in the Treatment of Advanced Tumors'. Among the patients, a 96-year-old veteran with melanoma achieved complete disappearance of the tumor after treatment.

2017

The company achieved another major breakthrough in NK cell culture technology. Multiple indicators, including NK cell purity, NK cell proliferation quantity and NK cell killing activity, rose to the international forefront. Jiake jointly developed clinical treatment products and technologies with Harvard Medical School and Brigham and Women's Hospital in the United States.

2016

As a core technology creator in the industry, Jiake developed rapidly. Its core technologies were integrated into the production processes of kits, culture media and other products, quickly capturing the market. After the final benchmarking of NK cell culture technology against the Japanese technology representative, Japanese technology withdrew from the Chinese market, and the company entered a brand-new era of rapid development.

2015

Jiake established an industry-university-research cooperation model with Sun Yat-sen University and other higher education institutions, forming an R&D force of 'in-house R&D team + external think tank'. Top experts in the industry were engaged as distinguished consultants, and multiple collaborative cooperation agreements were signed.

In the same year, a culture medium production line was built.


2014

Stem cell technology research was expanded. Jiake collaborated with the University of Hong Kong on the clinical trial project 'Gene Repair of Autologous Hematopoietic Stem Cells for the Treatment of Hereditary Metachromatic Leukodystrophy'. The first patient, Runrun from Taipei, received treatment at Shenzhen Second People's Hospital, and in the same year all of Runrun's indicators returned to normal levels.


2013

A GMP laboratory was built in Bao'an District, Shenzhen, and research was launched on immune cell isolation, induction, purification and expansion technologies. Multiple technical indicators reached internationally leading standards, and the technologies were transformed into production that year, capturing a substantial market share.


2012

Shenzhen Jiake Biotechnology Co., Ltd. was founded. In the same year, the company partnered with the Shenzhen Graduate School of Tsinghua University to carry out research on hair follicle stem cell technology and related fields.


Qualifications & Honors

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Invention Patent Certificate

Computer Software Copyright Registration Certificate

Computer Software Copyright Registration Certificate

Utility Model Patent Certificate

Utility Model Patent Certificate

×